A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma

The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three m...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1998, Vol.16 (4), p.337-340
Main Authors: BERG, W. J, MCCAFFREY, J, SCHWARTZ, L. H, MARIANI, T, MAZUMDAR, M, MOTZER, R. J
Format: Article
Language:English
Subjects:
Acridines - therapeutic use
Adult
Aged
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Blood tests
Cancer therapies
Carcinoma, Renal Cell - drug therapy
Chemotherapy
Cytokines
Cytotoxicity
Female
Humans
Immunotherapy
Kidney cancer
Kidney Neoplasms - drug therapy
Life expectancy
Male
Medical sciences
Metastasis
Middle Aged
Neutropenia
Patients
Pharmacology. Drug treatments
Pyrazoles - therapeutic use
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c264t-77de6aa89b73a5336ee9bdd118b95c31fe467c3b9f4f2e047910ed39c7c9af2b3
cites cdi_FETCH-LOGICAL-c264t-77de6aa89b73a5336ee9bdd118b95c31fe467c3b9f4f2e047910ed39c7c9af2b3
container_end_page 340
container_issue 4
container_start_page 337
container_title Investigational new drugs
container_volume 16
creator BERG, W. J
MCCAFFREY, J
SCHWARTZ, L. H
MARIANI, T
MAZUMDAR, M
MOTZER, R. J
description The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases. Patients were treated intravenously with 750 mg/m2 every three weeks. Twelve patients were enrolled in this study and all were evaluable for response and toxicity. Of the twelve patients, no major responses were achieved. Toxicity was mild, with three patients requiring a 20% dose reduction. At the dose and schedule used in this trial, pyrazoloacridine is inactive in renal cell carcinoma.
doi_str_mv 10.1023/A:1006143008040
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_216507544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>404192331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c264t-77de6aa89b73a5336ee9bdd118b95c31fe467c3b9f4f2e047910ed39c7c9af2b3</originalsourceid><addsrcrecordid>eNpVkM9LwzAYhoMobk7P3iSI17ovTZo03srwx2DgQT2Xr0nKOrq2Jq0y_3orG6iX97s838vLQ8glg1sGMZ9ndwxAMsEBUhBwRKYsUTwCKeQxmQKTKpJaqwk5C2EDAFwrcUomDEQspUyn5CWj3RqDo8slDf1gd7Qtabfz-NXWLRpf2apxtGpoh33lmj7Qz6pfU7Qf2BhnqXcN1tS4egz0pmraLZ6TkxLr4C4Od0beHu5fF0_R6vlxuchWkYml6COlrJOIqS4Ux4Rz6ZwurGUsLXRiOCudkMrwQpeijB0IpRk4y7VRRmMZF3xGrve9nW_fBxf6fNMOftwT8pjJBFQixAjN95DxbQjelXnnqy36Xc4g_3GYZ_k_h-PH1aF2KLbO_uH30kbg5gBgMFiXflRRhV8uVSxJU_4NlrR4YA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216507544</pqid></control><display><type>article</type><title>A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma</title><source>ABI/INFORM Global</source><source>Springer Link</source><creator>BERG, W. J ; MCCAFFREY, J ; SCHWARTZ, L. H ; MARIANI, T ; MAZUMDAR, M ; MOTZER, R. J</creator><creatorcontrib>BERG, W. J ; MCCAFFREY, J ; SCHWARTZ, L. H ; MARIANI, T ; MAZUMDAR, M ; MOTZER, R. J</creatorcontrib><description>The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases. Patients were treated intravenously with 750 mg/m2 every three weeks. Twelve patients were enrolled in this study and all were evaluable for response and toxicity. Of the twelve patients, no major responses were achieved. Toxicity was mild, with three patients requiring a 20% dose reduction. At the dose and schedule used in this trial, pyrazoloacridine is inactive in renal cell carcinoma.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1023/A:1006143008040</identifier><identifier>PMID: 10426668</identifier><identifier>CODEN: INNDDK</identifier><language>eng</language><publisher>Dordrecht: Kluwer</publisher><subject>Acridines - therapeutic use ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Blood tests ; Cancer therapies ; Carcinoma, Renal Cell - drug therapy ; Chemotherapy ; Cytokines ; Cytotoxicity ; Female ; Humans ; Immunotherapy ; Kidney cancer ; Kidney Neoplasms - drug therapy ; Life expectancy ; Male ; Medical sciences ; Metastasis ; Middle Aged ; Neutropenia ; Patients ; Pharmacology. Drug treatments ; Pyrazoles - therapeutic use ; Toxicity</subject><ispartof>Investigational new drugs, 1998, Vol.16 (4), p.337-340</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers 1998/1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c264t-77de6aa89b73a5336ee9bdd118b95c31fe467c3b9f4f2e047910ed39c7c9af2b3</citedby><cites>FETCH-LOGICAL-c264t-77de6aa89b73a5336ee9bdd118b95c31fe467c3b9f4f2e047910ed39c7c9af2b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/216507544/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/216507544?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,4024,11688,27923,27924,27925,36060,44363,74895</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1871588$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10426668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BERG, W. J</creatorcontrib><creatorcontrib>MCCAFFREY, J</creatorcontrib><creatorcontrib>SCHWARTZ, L. H</creatorcontrib><creatorcontrib>MARIANI, T</creatorcontrib><creatorcontrib>MAZUMDAR, M</creatorcontrib><creatorcontrib>MOTZER, R. J</creatorcontrib><title>A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases. Patients were treated intravenously with 750 mg/m2 every three weeks. Twelve patients were enrolled in this study and all were evaluable for response and toxicity. Of the twelve patients, no major responses were achieved. Toxicity was mild, with three patients requiring a 20% dose reduction. At the dose and schedule used in this trial, pyrazoloacridine is inactive in renal cell carcinoma.</description><subject>Acridines - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood tests</subject><subject>Cancer therapies</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Chemotherapy</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Life expectancy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neutropenia</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrazoles - therapeutic use</subject><subject>Toxicity</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>M0C</sourceid><recordid>eNpVkM9LwzAYhoMobk7P3iSI17ovTZo03srwx2DgQT2Xr0nKOrq2Jq0y_3orG6iX97s838vLQ8glg1sGMZ9ndwxAMsEBUhBwRKYsUTwCKeQxmQKTKpJaqwk5C2EDAFwrcUomDEQspUyn5CWj3RqDo8slDf1gd7Qtabfz-NXWLRpf2apxtGpoh33lmj7Qz6pfU7Qf2BhnqXcN1tS4egz0pmraLZ6TkxLr4C4Od0beHu5fF0_R6vlxuchWkYml6COlrJOIqS4Ux4Rz6ZwurGUsLXRiOCudkMrwQpeijB0IpRk4y7VRRmMZF3xGrve9nW_fBxf6fNMOftwT8pjJBFQixAjN95DxbQjelXnnqy36Xc4g_3GYZ_k_h-PH1aF2KLbO_uH30kbg5gBgMFiXflRRhV8uVSxJU_4NlrR4YA</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>BERG, W. J</creator><creator>MCCAFFREY, J</creator><creator>SCHWARTZ, L. H</creator><creator>MARIANI, T</creator><creator>MAZUMDAR, M</creator><creator>MOTZER, R. J</creator><general>Kluwer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0C</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>1998</creationdate><title>A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma</title><author>BERG, W. J ; MCCAFFREY, J ; SCHWARTZ, L. H ; MARIANI, T ; MAZUMDAR, M ; MOTZER, R. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c264t-77de6aa89b73a5336ee9bdd118b95c31fe467c3b9f4f2e047910ed39c7c9af2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Acridines - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood tests</topic><topic>Cancer therapies</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Chemotherapy</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Life expectancy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neutropenia</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrazoles - therapeutic use</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BERG, W. J</creatorcontrib><creatorcontrib>MCCAFFREY, J</creatorcontrib><creatorcontrib>SCHWARTZ, L. H</creatorcontrib><creatorcontrib>MARIANI, T</creatorcontrib><creatorcontrib>MAZUMDAR, M</creatorcontrib><creatorcontrib>MOTZER, R. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BERG, W. J</au><au>MCCAFFREY, J</au><au>SCHWARTZ, L. H</au><au>MARIANI, T</au><au>MAZUMDAR, M</au><au>MOTZER, R. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>1998</date><risdate>1998</risdate><volume>16</volume><issue>4</issue><spage>337</spage><epage>340</epage><pages>337-340</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><coden>INNDDK</coden><abstract>The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases. Patients were treated intravenously with 750 mg/m2 every three weeks. Twelve patients were enrolled in this study and all were evaluable for response and toxicity. Of the twelve patients, no major responses were achieved. Toxicity was mild, with three patients requiring a 20% dose reduction. At the dose and schedule used in this trial, pyrazoloacridine is inactive in renal cell carcinoma.</abstract><cop>Dordrecht</cop><pub>Kluwer</pub><pmid>10426668</pmid><doi>10.1023/A:1006143008040</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-6997
ispartof Investigational new drugs, 1998, Vol.16 (4), p.337-340
issn 0167-6997
1573-0646
language eng
recordid cdi_proquest_journals_216507544
source ABI/INFORM Global; Springer Link
subjects Acridines - therapeutic use
Adult
Aged
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Blood tests
Cancer therapies
Carcinoma, Renal Cell - drug therapy
Chemotherapy
Cytokines
Cytotoxicity
Female
Humans
Immunotherapy
Kidney cancer
Kidney Neoplasms - drug therapy
Life expectancy
Male
Medical sciences
Metastasis
Middle Aged
Neutropenia
Patients
Pharmacology. Drug treatments
Pyrazoles - therapeutic use
Toxicity
title A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A25%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20study%20of%20pyrazoloacridine%20in%20patients%20with%20advanced%20renal%20cell%20carcinoma&rft.jtitle=Investigational%20new%20drugs&rft.au=BERG,%20W.%20J&rft.date=1998&rft.volume=16&rft.issue=4&rft.spage=337&rft.epage=340&rft.pages=337-340&rft.issn=0167-6997&rft.eissn=1573-0646&rft.coden=INNDDK&rft_id=info:doi/10.1023/A:1006143008040&rft_dat=%3Cproquest_cross%3E404192331%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c264t-77de6aa89b73a5336ee9bdd118b95c31fe467c3b9f4f2e047910ed39c7c9af2b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=216507544&rft_id=info:pmid/10426668&rfr_iscdi=true